MX383682B - Tratamiento para cancer de mama usando una combinación de una formulación liposomal catiónica de taxano, una formulación no liposomal de taxano y un agente activo adicional. - Google Patents

Tratamiento para cancer de mama usando una combinación de una formulación liposomal catiónica de taxano, una formulación no liposomal de taxano y un agente activo adicional.

Info

Publication number
MX383682B
MX383682B MX2018008196A MX2018008196A MX383682B MX 383682 B MX383682 B MX 383682B MX 2018008196 A MX2018008196 A MX 2018008196A MX 2018008196 A MX2018008196 A MX 2018008196A MX 383682 B MX383682 B MX 383682B
Authority
MX
Mexico
Prior art keywords
taxane formulation
active agent
breast cancer
liposomal taxane
treatment
Prior art date
Application number
MX2018008196A
Other languages
English (en)
Other versions
MX2018008196A (es
Inventor
Hsin- Wei Teng
Hui- Yuan TSENG
Sih- Ting LIN
Original Assignee
Syncore Biotechnology Co Ltd
Cancap Pharmaceutical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syncore Biotechnology Co Ltd, Cancap Pharmaceutical Ltd filed Critical Syncore Biotechnology Co Ltd
Publication of MX2018008196A publication Critical patent/MX2018008196A/es
Publication of MX383682B publication Critical patent/MX383682B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción proporciona métodos para el tratamiento de cáncer de mama, que incluye cáncer de mama triple negativo. Dichos métodos comprenden la administración de (a) una formulación liposomal catiónica que comprende un taxano, (b) una formulación no liposomal que comprende un taxano y (c) un agente activo adicional. Dicho agente activo adicional de preferencia es gemcitabina.
MX2018008196A 2015-12-30 2016-12-28 Tratamiento para cancer de mama usando una combinación de una formulación liposomal catiónica de taxano, una formulación no liposomal de taxano y un agente activo adicional. MX383682B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562272772P 2015-12-30 2015-12-30
PCT/IB2016/058055 WO2017115301A1 (en) 2015-12-30 2016-12-28 Treatment of breast cancer using a combination of a cationic liposomal formulation of taxane, a non-liposomal formulation of taxane and a further active agent

Publications (2)

Publication Number Publication Date
MX2018008196A MX2018008196A (es) 2018-08-28
MX383682B true MX383682B (es) 2025-03-14

Family

ID=59227402

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018008196A MX383682B (es) 2015-12-30 2016-12-28 Tratamiento para cancer de mama usando una combinación de una formulación liposomal catiónica de taxano, una formulación no liposomal de taxano y un agente activo adicional.

Country Status (11)

Country Link
US (2) US20190015332A1 (es)
EP (1) EP3397244B1 (es)
JP (1) JP6912496B2 (es)
KR (1) KR20180093077A (es)
CN (1) CN108883068B (es)
AU (1) AU2016383697B2 (es)
CA (1) CA3009608C (es)
ES (1) ES2902576T3 (es)
MX (1) MX383682B (es)
TW (1) TWI760319B (es)
WO (1) WO2017115301A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI852903B (zh) * 2017-01-05 2024-08-21 杏國新藥股份有限公司 胰臟癌治療
DE112021004478T5 (de) 2020-08-25 2023-09-14 Seer, Inc. Zusammensetzungen und verfahren zur bestimmung von proteinen und nukleinsäuren
JP2026505783A (ja) * 2023-01-31 2026-02-18 石薬集団中奇制薬技術（石家庄）有限公司 腫瘍を治療するためのパクリタキセルカチオンリポソームの使用
US20250049713A1 (en) * 2023-04-13 2025-02-13 Massachusetts Institute Of Technology Lipid nanoparticles for delivery of agents

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW197439B (es) 1991-04-04 1993-01-01 Ueno Pharmaceutics Applic Res Co Ltd
US5283253A (en) 1991-09-23 1994-02-01 Florida State University Furyl or thienyl carbonyl substituted taxanes and pharmaceutical compositions containing them
AU3140093A (en) 1991-11-22 1993-06-15 University Of Mississippi, The Synthesis and optical resolution of the taxol side chain and related compounds
US5200534A (en) 1992-03-13 1993-04-06 University Of Florida Process for the preparation of taxol and 10-deacetyltaxol
EP0642586A4 (en) 1992-05-21 1995-11-29 Penn State Res Found CULTURAL -i (TAXUS) FABRIC AS A SOURCE OF TAXOL, RELATED TAXANS AND OTHER NEW ANTI-TUMOR / ANTI-VIRAL SUBSTANCES (01/20/94).
US5274137A (en) 1992-06-23 1993-12-28 Nicolaou K C Intermediates for preparation of taxols
US5294637A (en) 1992-07-01 1994-03-15 Bristol-Myers Squibb Company Fluoro taxols
US5202448A (en) 1992-08-14 1993-04-13 Napro Biotherapeutics, Inc. Processes of converting taxanes into baccatin III
CA2100808A1 (en) 1992-10-01 1994-04-02 Vittorio Farina Deoxy paclitaxels
FR2696462B1 (fr) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé d'obtention de la désacétyl-10 baccatine III.
FR2696461B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Nouveaux dérivés d'analogues du taxol, leur préparation et les compositions qui les contiennent.
FR2696458B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Procédé de préparation de dérivés du taxane.
FR2696463B1 (fr) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé d'obtention de la désacétyl-10 baccatine III.
FR2696464B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Nouveau procédé d'estérification de la baccatine III et de la désacétyl-10 baccatine III.
US5279949A (en) 1992-12-07 1994-01-18 Board Of Trustees Operating Michigan State University Process for the isolation and purification of taxol and taxanes from Taxus spp
US5415869A (en) 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
AU3740997A (en) 1996-08-26 1998-03-19 Bristol-Myers Squibb Company Sulfenamide taxane derivatives
WO1998022451A1 (en) 1996-11-19 1998-05-28 Daiichi Pharmaceutical Co., Ltd. Taxol derivatives
US5977386A (en) 1996-12-24 1999-11-02 Bristol-Myers Squibb Company 6-thio-substituted paclitaxels
US7288665B1 (en) 1997-08-18 2007-10-30 Florida State University Process for selective derivatization of taxanes
JPH1192468A (ja) 1997-09-17 1999-04-06 Yakult Honsha Co Ltd 新規なタキサン誘導体
AU741433B2 (en) 1997-10-08 2001-11-29 Bio Research Corporation Of Yokohama Taxoid derivatives and process for producing the same
ATE444062T1 (de) 2002-06-26 2009-10-15 Medigene Ag Herstellung einer kationisch liposomalen zubereitung, einen lipophilen wirkstoff enthaltend
JP5700909B2 (ja) * 2005-05-04 2015-04-15 メディゲーネ アクチエンゲゼルシャフトＭｅｄｉＧｅｎｅ ＡＧ パクリタキセルを含む陽イオン性リポソーム製剤を投与する方法
RU2448697C2 (ru) * 2006-03-22 2012-04-27 Медигене Аг Лечение рака молочной железы, негативного по трем рецепторам
CN103933579A (zh) * 2014-04-03 2014-07-23 华侨大学 一种阳离子脂质体及其制备方法和应用

Also Published As

Publication number Publication date
KR20180093077A (ko) 2018-08-20
JP2019505582A (ja) 2019-02-28
MX2018008196A (es) 2018-08-28
CA3009608A1 (en) 2017-07-06
CA3009608C (en) 2024-06-11
AU2016383697A1 (en) 2018-07-19
US20220313608A1 (en) 2022-10-06
TWI760319B (zh) 2022-04-11
WO2017115301A1 (en) 2017-07-06
CN108883068B (zh) 2021-09-10
CN108883068A (zh) 2018-11-23
JP6912496B2 (ja) 2021-08-04
AU2016383697B2 (en) 2021-11-18
ES2902576T3 (es) 2022-03-29
EP3397244A1 (en) 2018-11-07
TW201722423A (zh) 2017-07-01
EP3397244A4 (en) 2019-09-04
US20190015332A1 (en) 2019-01-17
EP3397244B1 (en) 2021-10-06

Similar Documents

Publication Publication Date Title
CL2018000706A1 (es) Derivados de pirazolopirimidina como inhibidores btk para el tratamiento del cancer.
CO2019008487A2 (es) Compuesto de quinazolina
MX2018012486A (es) Composiciones para aplicacion topica de compuestos.
EP4349414A3 (en) Methods and formulations for transdermal administration
MX378273B (es) Compuestos activos hacia bromodominios.
MX390014B (es) Compuestos de dinucleótidos cíclicos y métodos de uso.
CL2017000080A1 (es) Métodos para tratar el cáncer con inhibidores de tigit y agentes contra el cáncer
MY188139A (en) Sodium channel modulators for the treatment of pain
DOP2017000307A (es) Formulación sólida oral que contiene irinotecán y método de preparación de la misma.
AR108021A1 (es) Conjugados de anticuerpo-principio activo (adcs) de inhibidores de ksp con anticuerpos anti-b7h3
MX2019003134A (es) Terapia de combinacion.
MX375254B (es) Una composición antimicrobiana farmacéutica o veterinaria intramamaria que comprende un poliéter ionóforo, o un uso de la misma para tratar mastitis.
PH12015502616A1 (en) Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
MX376118B (es) Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant.
MX2018013873A (es) Irinotecan nanoliposomico para usarse en el tratamiento del cancer de pulmon de celulas pequeñas.
CL2015002171A1 (es) Métodos de tratamiento de la dificiencia de hierro con pirofosfato férrico soluble.
MX383682B (es) Tratamiento para cancer de mama usando una combinación de una formulación liposomal catiónica de taxano, una formulación no liposomal de taxano y un agente activo adicional.
MX2017010341A (es) Terapia para cancer con un parvovirus combinado con bevacizumab.
MX2016004078A (es) Formulacion de atazanavir y cobicistat para el tratamiento del virus de inmunodeficiencia humana (vih).
UA118474C2 (uk) (s)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині
BR112018014723A2 (pt) fantasmas bacterianos para o tratamento de câncer
PH12018502139A1 (en) Phosphaplatin liquid formulations
UA116499C2 (uk) (r)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині
CO2017000354A2 (es) Desmopresina estabilizada